Search Results
You are looking at 111 - 120 of 130 items for
- Author: Margaret Tempero x
- Refine by Access: All x
It Just Keeps Getting Better!
Margaret Tempero
Giving Thanks
Margaret Tempero
News About the Tiny Pharmacists Within Us
Margaret Tempero
Did the IRB Approve This?
Margaret Tempero
The Greatest Show on Earth!
Margaret Tempero
Getting What You Pay For: Finding Value in Cancer Care
Margaret Tempero
Understanding Cancer Risk—Genes Matter!
Margaret Tempero
Introducing the New Editor-in-Chief
Margaret Tempero
Multidisciplinary Management of Pancreatic Cancer
Margaret A. Tempero
Pancreatic cancer remains a vexing treatment challenge, with a cure rate that remains just 7%. Two effective regimens—gemcitabine/nab-paclitaxel and FOLFIRINOX—have improved outcomes and are being used earlier in the disease. However, meaningful differences in outcomes may not be realized without novel strategies. Targeting of the immune system is an active area of research.
NCCN Guidelines Updates: Pancreatic Cancer
Margaret A. Tempero
Outcomes for pancreatic cancer are becoming less discouraging with the refinement of molecular profiling, both germline and somatic, and beneficial effects seen with adjuvant chemotherapy. The NCCN Guidelines for Pancreatic Adenocarcinoma reflect these advances, and recommend that clinicians consider germline testing for all patients with pancreatic cancer and consider a molecular analysis for those with metastatic disease. The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it.
